Related Experiment Video
Updated: Feb 5, 2026

Production and Visualization of Bacterial Spheroplasts and Protoplasts to Characterize Antimicrobial Peptide Localization
Published on: August 11, 2018
Novel Self-Assembled Micelles Based on Cholesterol-Modified Antimicrobial Peptide (DP7) for Safe and Effective
Rui Zhang1,2, Fengbo Wu1,2, Lei Wu1,2
1State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Sichuan, China.
Abstract:
Owing to their broad-spectrum antibacterial properties, multitarget effects, and low drug resistance, antimicrobial peptides (AMPs) have played critical roles in the clinical therapy of drug-resistant bacterial infections. However, the potential hazard of hemolysis following systemic administration has greatly limited their application. Here, we developed a novel AMP derivative, DP7-C, by modifying a formerly identified highly active AMP (DP7) with cholesterol to form an amphiphilic conjugate. The prepared DP7-C easily self-assembled into stable nanomicelles in aqueous solution. The DP7-C micelles showed lower hemolytic activity than their unconjugated counterparts toward human red blood cells and a maximum tolerated dose of 80 mg/kg of body weight in mice via intravenous injection, thus demonstrating improved safety. Moreover, by eliciting specific immunomodulatory activities in immune cells, the DP7-C micelles exerted distinct therapeutic effects in zebrafish and mouse models of infection. In conclusion, DP7-C micelles may be an excellent candidate for the treatment of bacterial infections in the clinic.
Insights
Researchers developed DP7-C, a modified antimicrobial peptide (AMP), to combat drug-resistant bacteria. This novel conjugate forms nanomicelles with reduced hemolysis and enhanced safety, showing promise for clinical bacterial infection treatment.
Area of Science:
- Biochemistry
- Nanotechnology
- Pharmacology
Background:
- Antimicrobial peptides (AMPs) are crucial for treating resistant bacterial infections due to their broad-spectrum activity and low resistance.
- Systemic administration of AMPs is limited by potential hemolysis, posing a safety concern.
Purpose of the Study:
- To develop a safer and effective antimicrobial agent by modifying a known AMP.
- To create a novel amphiphilic conjugate, DP7-C, and evaluate its self-assembly, safety, and therapeutic efficacy.
Main Methods:
- A highly active AMP (DP7) was conjugated with cholesterol to create the amphiphilic derivative DP7-C.
- DP7-C was characterized for its self-assembly into nanomicelles in aqueous solution.
- Hemolytic activity, maximum tolerated dose in mice, and therapeutic effects in zebrafish and mouse infection models were assessed.
Main Results:
- DP7-C self-assembled into stable nanomicelles.
- DP7-C micelles exhibited significantly lower hemolytic activity compared to unconjugated DP7.
- DP7-C demonstrated a high maximum tolerated dose (80 mg/kg) in mice and therapeutic effects in infection models.
Conclusions:
- DP7-C nanomicelles represent an improved, safer alternative to traditional AMPs.
- The enhanced safety profile and therapeutic efficacy suggest DP7-C is a promising candidate for treating bacterial infections.
- This study highlights the potential of cholesterol conjugation for developing advanced AMP-based therapeutics.
Related Concept Videos
Antimicrobial Effectiveness
Cholesterol: Significance and Regulation
Considering cholesterol and...
Peptide Bonds
One-Compartment Open Model for Extravascular Administration: Zero-Order Absorption Model
Zero-order absorption maintains a steady rate irrespective of the amount of drug left to be absorbed, making it a constant process. In the...
Gram-negative Bacterial Protein Secretion Systems
Two-Compartment Open Model: Extravascular Administration
The absorption exponent (ka) indicates the speed at which the drug...

